J

Johnson & Johnson

Makes prescription drugs and medical devices

Global Process Owner - Product Quality Reporting

Full-TimePosted on 10/13/2026Deadline 10/23/26
€119.2k - €204.4k+ Annual target bonus + Sales commissions
Expert
Bachelor's, Master's
Cork, Ireland+1 moreMore locations: Beerse, Belgium
Hybrid
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A minimum of a Bachelor's degree is required; degrees in pharmacy, chemistry, engineering, life sciences, statistics, or a related discipline are preferred.
  • At least 12 years of relevant experience in the pharmaceutical, biotechnology, medical-device, or similarly regulated industry, including substantial Quality Assurance and/or Regulatory Compliance experience.
  • Demonstrated knowledge of global GxP and cGMP requirements and experience translating requirements into sustainable global processes and controls.
  • Experience leading complex, global, cross-functional programs or Quality System processes in a matrix environment.
  • Experience identifying and managing GxP compliance risk, including developing risk-based remediation strategies and concise reporting of risk and status.
  • Demonstrated ability to define strategy and translate it into executable plans, governance, measures, and sustained change.
  • Ability to connect across a large, diverse organization and manage multiple priorities with sound judgment and urgency.
Responsibilities
  • Own the end-to-end BPDR/FAR and APR/PQR process architecture, governance, standards, and lifecycle for Innovative Medicine; establish scope, decision rights, roles and responsibilities, interfaces, controls, escalation pathways, and execution expectations.
  • Provide global process leadership for BPDR and FAR and establish the governance and decision framework for timely, consistent, traceable, and compliant assessments and filings; serve as, or designate through approved governance, the ultimate process-level filing decision authority in line with procedures and delegated accountability.
  • Act as global process owner for end-to-end Product Quality Review and Annual Product Review, setting direction for data gathering, holistic product review, data and trend interpretation, risk identification, reporting, review, approval, and follow-through on improvements.
  • Connect signals and outputs across BPDR/FAR, APR/PQR, complaints, investigations, NC/CAPA, escalation, continued process verification, stability, and other relevant inputs to strengthen proactive product-risk identification and management.
  • Drive one globally consistent process framework while defining controls for justified local or regulatory variation; simplify workflows, reduce ambiguity, improve traceability, and clarify handoffs among global, regional, platform, site, and functional teams.
  • Define, maintain, and analyze process KPIs and quality/compliance metrics, including timeliness, status, execution quality, trends, recurring issues, and effectiveness; make process insights available for management-review and Quality governance forums.
  • Own business requirements and end-to-end data governance for enabling systems, automation, analytics, and reporting; partner with Digital Quality & Innovation and technology teams to support a coherent digital Quality ecosystem and reliable, inspection-ready data.
  • Lead the global Community of Practice and process-owner network; build process capability through guidance, learning, communications, role clarity, knowledge sharing, and structured adoption of process and technology changes.
  • Maintain process inspection readiness; support health-authority inspections and audits; ensure timely responses to observations or process gaps; translate internal and external insights into sustainable improvements; and monitor and influence evolving regulatory requirements.
  • Monitor process performance and emerging requirements, prioritize improvements based on compliance and business risk, sponsor remediation when needed, and verify sustained effectiveness of changes.
  • Lead globally dispersed contributors and influence across functions without relying on direct authority; partner with process executors and content owners to enable sound decisions while preserving clear execution and product-decision accountability; foster alignment with Value Chain Management and MSAT.
  • Where applicable, lead employees and contractors, set priorities, manage performance and development, and ensure resources and capabilities align with the highest-risk and highest-value process needs.
  • Deliver approved end-to-end process architecture, governance, RACI/decision-rights models, and controlled global standards for BPDR/FAR and APR/PQR.
  • Deliver consistent, timely, traceable, and compliant BPDR/FAR assessment and filing performance, and effective risk-based APR/PQR execution that produces meaningful insights and follow-up actions.
  • Provide integrated process metrics, dashboards, trend analysis, and management-review reporting with clear action ownership.
  • Develop a prioritized digital and data roadmap with business requirements, data ownership, controls, and adoption measures.
  • Demonstrate inspection readiness, timely remediation of gaps, and sustained effectiveness of process improvements.
  • Maintain an active global process-owner network and Community of Practice with clear capability expectations and reusable learning.
  • Set global process strategy, target state, governance model, standards, and performance expectations for BPDR/FAR and APR/PQR.
  • Approve proposed global process changes and prioritize the process-improvement and digital roadmap through established QM&D governance.
  • Define escalation criteria and ensure complex or high-risk decisions reach the appropriate accountable governance body.
  • Provide or coordinate designated ultimate process-level BPDR/FAR filing decision authority, subject to approved procedures and legal/regulatory accountabilities.
  • Accept process risks or escalate them to the appropriate Quality governance body when acceptance exceeds delegated authority.
Desired Qualifications
  • An advanced scientific, engineering, regulatory, data/analytics, or business degree is preferred.
  • Direct experience with BPDR, FAR, APR, PQR, product-quality surveillance, continued process verification, health-authority reporting, or related product lifecycle processes.
  • Experience as a Global Process Owner, business process owner, product owner, or Quality System owner.
  • Experience with global process standardization, digital workflow enablement, data governance, analytics, and inspection-ready reporting.
  • Experience supporting GxP audits and health-authority inspections.
  • Working knowledge of quality-risk-management and quality-management-system principles.
  • Preferred skills include Business Process Management (BPM), Business Requirements Analysis, Compliance Management, Data Savvy, Fact-Based Decision Making, Forward Thinking, ISO 9001, Mentorship, Process Governance, Process Optimization, Quality Control (QC), Quality Standards, Quality Validation, Stakeholder Engagement, Standard Operating Procedure (SOP), Tactical Planning, Tactical Thinking, and Technical Credibility.
  • Strong analytical, decision-making, influencing, negotiation, written, and verbal communication skills.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

INACTIVE